CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Clarithromycin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00445692
NCT00445692Phase 2Completed
CompareCT.gov

Maintenance Therapy With Lenalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma

Fred Hutchinson Cancer Center·interventional·Posted Mar 9, 2007·Updated Nov 13, 2019

In Brief

A Phase 2 clinical trial evaluating Clarithromycin, Dexamethasone, and 1 other intervention for DS Stage I Plasma Cell Myeloma and 3 related conditions. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This phase II trial studies lenalidomide, dexamethasone, and clarithromycin in treating patients who have undergone stem cell transplant for multiple myeloma. Biological therapies, such as lenalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone and clarithromycin may be an effective treatment for multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 9, 2007
Enrollment StartJan 10, 2007
Primary CompletionApr 24, 2017
TodayJul 2, 2026
Enrollment to primary: 10.3 yearsPosted 19.3 years ago

Interventions

Clarithromycindrug

Given Orally (PO)

Dexamethasonedrug

Given PO

Lenalidomidedrug

Given Orally (PO)